← Back to patent-cliff list
Larotinib Mesylate
Tier C — Watch / tradeLarotinib Mesylate
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：EGFR, HER2, HER4, RIPK2, IRAK1, BTK, BLK, IGF1R
Indications (approved)：Oesophageal cancer, 食管鳞状细胞癌, Solid tumour, Pancreatic cancer
Regional status
US
-
EU
-
China
Phase III
2021-01-21
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Larotinib Mesylate?
Approved indications include: Oesophageal cancer, 食管鳞状细胞癌, Solid tumour, Pancreatic cancer.
When does the Larotinib Mesylate patent expire?
No public expiry year is available for Larotinib Mesylate yet; this page updates once verified.
How do I get a quote for Larotinib Mesylate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06